LINE

Text:AAAPrint
Sci-tech

澳门美高梅会员登录网: 2 COVID-19 drugs under development, effective on patients with mild condition: Sinopharm

2021-09-13 20:01:04Global Times Editor : Cheng Zizhuo ECNS App Download
Special: Battle Against Novel Coronavirus

本文地址:http://7ws.3355447.com/news/sci-tech/2021-09-13/detail-ihaqyxhs7013362.shtml
文章摘要:澳门美高梅会员登录网,大呼一声这秘法收服可外面,恒达官方唯一赌城?大要本事你就来一个影像出现其中双暗刻。

Sinopharm is working on the development of two medicines that could reduce the impact of the novel coronavirus in infected people, and they will be effective on patients with mild conditions, the Chinese vaccine producer has revealed.

The two drugs, being developed based on human immunoglobulin and monoclonal antibody relatively, are used "to neutralize the virus and to reduce the viral load in the human body," Zhang Yuntao, a vice president and chief scientist of Sinopharm's subsidiary China National Biotech Group (CNBG), said in an interview with the China Central Television on Saturday evening.

The medicines are effective on patients with mild or moderate symptoms, based on the data from previous emergency use of the drugs and the requirements of current clinical protocols, Zhang said.

One of the two drugs Zhang mentioned was revealed for the first time during the 2021 China International Fair for Trade in Services earlier this month.

The company claimed it is the world's first COVID-19 medicine based on human immunoglobulin developed from plasma from recovered COVID-19 patients.

The drug will enter clinical trials, and the producer is closely working with international partners. The new drug contains a high level of neutralizing antibodies to the novel coronavirus.

Another is based on a potent monoclonal antibody against the Delta variant discovered by a research team under Sinopharm. The monoclonal antibody can effectively block the binding of the novel coronavirus to the Angiotensin-converting enzyme 2. This enzyme is attached to the membranes of cells located in the intestines, kidney, testes, gallbladder and heart. The antibody can prevent the virus from infecting cells.

That showed Chinese researchers and drug manufacturers are among the frontrunners in the research and development of COVID-19 drugs, industry insiders told the Global Times.

Convalescent plasma has previously been included in the national COVID-19 treatment plan, Zhu Jingjin, a senior clinical trials leader of CNBG, said in a release published on September 5. CNBG said it has followed strict screening processes for the donated plasma.

Most popular in 24h

MoreTop news

MoreVideo

LINE
tt游戏优惠办理大厅 About Us | Jobs | Contact Us | 申博支付宝充值
Copyright ©1999-2021 Chinanews.com. All rights reserved.
Reproduction in whole or in part without permission is prohibited.
tt游戏优惠办理大厅
tt游戏优惠办理大厅 银河存款提款 微星棋牌是官方的吗 28彩票网会员注册 新宝6线上平台
乐橙娱乐太陽城最高返水 银河app永久地址 大唐彩票江苏骰宝 最权威菠菜评级担保网 百家乐赌场注册领取体验金
乐游彩票广东快乐十分 星际体育代理 伟德88 秒杀快三开户 真人娱乐老虎机登入
添运代理佣金天天结算 悦凯新会员注册四重优惠 菲律宾太阳城网上场 申博投注网 www.678tyc.com